NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»06/11/2009 [Industry news]
Beike Biotech invests in Japanese company

Shenzhen Beike Biotechnology, China\'s leading stem cell research and regenerative medicine company, has entered into an agreement with Yokohama-based Biomaster for investment in its advanced technologies.

 
Shenzhen Beike Biotechnology, China\'s leading stem cell research and regenerative medicine company, has entered into an agreement with Yokohama-based Biomaster for investment in its advanced technologies. Biomaster specializes in research and commercialization of adipose-based stem cell therapies. Beike, along with two investment companies, has taken a significant share in Biomaster, secured a seat on the board, and is involved in the company\'s strategic positioning in preparation for an eventual IPO. Since its inception in 2002, Biomaster is said to have been a leading innovator in the field of adipose-derived stem cell regenerative technology. Biomaster\'s scientists have published ten articles in leading international journals related to stem cell technology. Beike Biotechnology is said to offer Biomaster a strategic launch pad for its technologies through its extensive clinical and research networks in China, Southeast Asia and Central America. \"This deal has created a powerful partnership that plays to our companies\' respective advantages,\" stated Dr Shoko Murase, President of Biomaster. \"Biomaster is uniquely positioned as the only facility allowed by law to offer stem-cell based therapy to the Japanese public. From a healthcare standpoint, our partnership with Beike will extend our services to patients at Beike\'s affiliated clinical research institutes in China and worldwide. Biomaster\'s R&D will also benefit from Beike\'s wide network of research laboratories, international partners and technical resources, enabling our company to accelerate future product development timelines and to utilize the favorable research environment in China.\" The increased capital from this investment will enable Biomaster to advance its strategic aims of developing stem cell-based hair growth, spinal repair and organ regeneration therapies. Biomaster will benefit from Beike\'s extensive clinical research network and broad access to the growing Chinese medical market. Dr Sean Hu, CEO and Chairman of Beike Biotechnology expressed his support for the contract saying, \"Biomaster\'s technologies complement our own work. This is a logical step that will harness both companies\' strengths. We look forward to providing technical and financial assistance in bringing their future regenerative technologies to the market. I am confident that Beike\'s world-class stem cell laboratories and research teams can efficiently scale-up Biomaster\'s current research efforts, accelerating R&D timelines and get treatment to the patients who need it.\" Biomaster was granted a license by the Japanese Ministry of Health to operate Cellport Yokohama as a private clinic in Yokohama, Kanagawa-ken, Japan. The clinic currently treats patients using CAL, a proprietary technology which allows doctors to use fat extracted from other body areas (such as stomach or thighs) for cosmetic and therapeutic purposes.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.